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Abstract
Zinc finger nucleases (ZFNs) consist of zinc fingers as DNA-binding module and the non-specific DNA-cleavage
domain of the restriction endonuclease FokI as DNA-cleavage module. This architecture is also used by TALE
nucleases (TALENs), in which the DNA-binding modules of the ZFNs have been replaced by DNA-binding domains
based on transcription activator like effector (TALE) proteins. Both TALENs and ZFNs are programmable nucleases
which rely on the dimerization of FokI to induce double-strand DNA cleavage at the target site after recognition of the
target DNA by the respective DNA-binding module. TALENs seem to have an advantage over ZFNs, as the
assembly of TALE proteins is easier than that of ZFNs. Here, we present evidence that variant TALENs can be
produced by replacing the catalytic domain of FokI with the restriction endonuclease PvuII. These fusion proteins
recognize only the composite recognition site consisting of the target site of the TALE protein and the PvuII
recognition sequence (addressed site), but not isolated TALE or PvuII recognition sites (unaddressed sites), even at
high excess of protein over DNA and long incubation times. In vitro, their preference for an addressed over an
unaddressed site is > 34,000-fold. Moreover, TALE-PvuII fusion proteins are active in cellula with minimal
cytotoxicity.
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Introduction
Precision genome engineering requires highly specific
nucleases that, even within the context of a complex genome,
cleaves only a single site to prevent genotoxic off-target
activity. So far, a variety of different architectures has been
used to generate such highly specific nucleases [1-5]. Although
some natural homing endonucleases could be engineered to
fulfill this requirement [6-8], these “meganucleases“ are not
easily re-programmable, in contrast to the zinc finger nucleases
[9-16] introduced by Kim et al. [15]. Typically, to generate a
ZFN, the non-specific DNA-cleavage domain of the Type IIS
restriction endonuclease FokI is fused to an array of three or
four zinc fingers, which constitute the DNA recognition module
that can be varied to recognize distinct DNA sequences
[10,14]. After transcription activator-like effector (TALE)
proteins had been discovered [17-19] and shown that they
display a simple code for DNA recognition [20-22], it became
clear that the DNA binding domain of TALE proteins could be
used instead of zinc finger arrays for generating customizable
nucleases [23-26]. Because of their simple design, predictable
sequence specificity and easy synthesis [27-30], TALE-based
nucleases (TALENs) seem to become the nucleases of choice
for genome engineering [31-35]. Recently, a new powerful
technique for genome engineering applications has been
described based on the programmable RNA-guided DNA
endonuclease Cas9 from a prokaryotic type II CRISPR system
[36-38]. The endonuclease is guided to the target DNA by a
short RNA molecule that contains a sequence complementary
to the cleavage site fused to an invariant RNA part. In contrast
to ZFNs and TALENs, this architecture does not rely on the
fusion with an external nuclease domain [4].
Typical ZFNs and TALENs contain the FokI DNA-cleavage
module [39,40] that in its natural configuration recognizes a
non-palindromic sequence and cleaves the DNA
asymmetrically 9 and 13 nucleotides downstream of its
recognition site [41]. Double-strand cleavage requires the
dimerization of a FokI monomer bound to its recognition site via
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its catalytic domain with a second monomer by recruiting the
latter either from solution [42] or, preferably, from another
monomer bound to a second recognition site, which can be, but
does not need to be, nearby [43]. In ZFNs and TALENs, the
DNA-binding domains are designed to recognize two adjacent
DNA sequences, and to induce cleavage of the DNA between
the target sequences upon FokI dimerization. As pointed out by
Halford and co-workers [44], “this strategy fails to take account
of the fact that the catalytic domains of FokI can dimerize
across distant sites or even at a solitary site. Additional copies
of either target sequence elsewhere in the chromosome must
elicit off-target cleavages”. The reaction mechanism of FokI,
therefore, raises some concerns about the possibility of
targeting ZFNs and TALENs to unique DNA sites. To minimize
this risk, specially engineered obligate heterodimeric FokI
cleavage domains have been used in ZFNs [45,46]. Indeed, a
recent study had identified several off-target cleavage sites in
vivo by a genome-wide integration site analysis that mapped
the actual in vivo cleavage activity of four ZFN pairs targeting
CCR5 or ILRG genes [47]. In another study, the off-target
cleavage specificities of ZFNs targeting CCR5 and VEGF-A
genes were analyzed by in vitro selection; several of these
sites were found to be cleaved also in cultured human cells
[48].
There are alternative architectures of programmable
nucleases substituting the nonspecific FokI cleavage domain.
We had produced a programmable nuclease by fusing a triple-
helix-forming oligonucleotide (TFO) as binding module with the
single-chain (sc) variant of PvuII as cleavage module and
shown that this chimera had a preference for cleavage of an
“addressed” site, i.e. a PvuII site flanked by a triple-helix-
forming site, compared to an “unaddressed” site, i.e. a PvuII
site not flanked by a triple-helix-forming site, by >1000-fold [49].
This specificity, however, was only achieved, when the
substrate was pre-incubated in the absence of Mg2+ and the
reaction started by the addition of Mg2+. This would exclude an
application in vivo, unless one would “cage” the enzyme with a
photo-labile group and start the reaction by “decaging” with
light [50]. In addition, the TFO-scPvuII constructs can only be
delivered by “profection” into cells [51,52].
The TFO-scPvuII study showed that there are alternatives to
the catalytic domain of FokI as DNA-cleavage module. This
was subsequently validated for protein chimeras comprising
the restriction endonuclease PvuII as DNA-cleavage module in
combination with an inactivated homing endonuclease, I-SceI*
[53], or a zinc finger array [54] as a DNA-binding module and
recently with fusions exploiting the specific monomeric
nuclease TevI [55]. Using a site-specific rather than a non-
specific nuclease as cleavage module in a programmable
nuclease adds an extra element of specificity, given by the
recognition site of the restriction endonuclease in addition to
the recognition site of the DNA-binding module. This increase
in specificity became evident in a comparison between zinc
finger-FokI and zinc finger-PvuII fusion proteins which
demonstrated that the PvuII constructs, even at high
concentrations and after long incubation times, did not show
off-target cleavage in vitro [54]. Furthermore, two recent papers
showed that the nonspecific FokI cleavage domain in TALENs
could be replaced by TevI, introducing double-strand breaks
[56], and MutH, introducing strandspecific nicks [57].
In this study, we investigated whether variant TALENs can
be produced by fusing PvuII as a DNA-cleavage module to
TALE proteins. We demonstrate that with appropriate linkers
PvuII-based TALENs are able to specifically cleave the
addressed target sites, even at a large excess of enzyme over
substrate and after long incubation times. We conclude that
PvuII-based TALENs are a promising alternative to FokI-based
TALENs.
Materials and Methods
Design and construction of TALE-PvuII fusion proteins
The AvrBs3 TALE protein was truncated at the N-terminus
by 152 amino acids and at the C-terminus by 250 and 215
amino acids, leaving 28 or 63 amino acids, respectively, after
the last repeat. The truncated proteins were fused to the PvuII
high fidelity variant T46G [58] or alternatively to the single-
chain PvuII variant [59] with a 16 amino acid linker, L [=
SSVIPNRGVTKQLVKG, based on the linker used in [54]]. All
proteins contained an N-terminal Strep-tag and a C-terminal
His6-tag. The following constructs were generated: Strep-
AvrBs3-63-L-PvuIIT46G-His6, Strep-AvrBs3-28-L-PvuIIT46G-His6,
Strep-AvrBs3-28-PvuIIT46G-His6, Strep-AvrBs3-L-PvuIIT46G-His6,
Strep-AvrBs3-63-L-scPvuIIT46G-His6, Strep-AvrBs3-28-L-
scPvuIIT46G-His6.
Protein expression and purification
For expression and purification, the Escherichia coli strain
XL10-Gold (Stratagene) transformed with the pLGM plasmid
containing the sequence for the PvuII DNA-methyltransferase
was used. Cultures were induced with 1 mM isopropyl-ß-D-
thiogalactopyranoside at 37°C at an OD600nm of 0.7. The TALE-
scPvuIIT46G-producing cells were harvested after 4 h at 37°C,
whereas the TALE-PvuIIT46G-producing cells were harvested
after an overnight induction at 23°C. The cells were
resuspended in 30 mM K-phosphate, 1 M NaCl, 1 mM DTT, 1
mM EDTA, 1 mM phenyl methane sulfonyl fluoride (PMSF),
0.01% w/v Lubrol, pH 7.8 and lysed by sonification. Cell debris
was removed by centrifugation (>17000 g) for 30 min at 4°C.
The His6-tagged proteins were purified by affinity
chromatography over Ni-NTA agarose (Qiagen). The Ni-NTA
agarose was equilibrated with the resuspension buffer and
incubated with the recombinant protein preparations for 1 h at
4°C. The first wash step was performed with the resuspension
buffer and the second wash step with 30 mM K-phosphate, 500
mM NaCl, 1 mM EDTA, 1 mM DTT, 0.01% Lubrol, 15 mM
imidazole and 1 mM PMSF, pH 7.8. The eluted proteins
(elution buffer: 50 mM K-phosphate, 300 mM NaCl, 250 mM
imidazole, pH 8) were further purified by a heparin column
chromatography on an ÄKTA HPLC (GE Healthcare) using a
gradient elution from 0.3 to 1 M KCl in 30 mM K-phosphate, 1
mM DTT, 1 mM EDTA, 1 mM PMSF, 0.01% Lubrol, pH 7.8.
The elution of the proteins started between 500 and 550 mM
KCl. Fractions with pure protein were dialyzed overnight at 4°C
against 30 mM K-phosphate, 550 mM KCl, 1 mM DTT, 1 mM
EDTA, 60% v/v glycerol, pH 7.8 and stored at -20°C. The
TALE-PvuII Fusion Proteins
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protein concentration was determined by measuring the
absorbance at 280 nm [the molar extinction coefficient was
determined according to Pace et al. [60]]. The progress of the
protein purification was monitored by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis analysis (Figure S1).
Plasmid cleavage assay
To characterize the cleavage rates of the different TALE-
PvuII nucleases with different targets, plasmid substrates were
generated. For this purpose, the TALE-PvuII target sites were
inserted as a cassette into the pAT153 vector (Table S1). The
AvrBs3 recognition site had been optimized based on the RVD
code according to Boch et al. [21]. As an unaddressed target, a
pAT153-derived plasmid with just one PvuII site was used. For
the analysis of the kinetics with near-stoichiometric
concentrations of substrate and enzyme, 8 nM substrate were
incubated with 8 nM active enzyme (scPvuII acts as a
monomer) in 20 mM Tris-Ac, 50 or 120 mM KCl, respectively, 1
mM Mg-Ac, pH 7.5 at 37°C. Taking the enzyme dilution into
account, the ionic strength of the reaction mixture was between
145-150 mM. The kinetics were analyzed after defined time
points (up to 24 h) by agarose gel electrophoresis and ethidium
bromide gel staining; documentation had been performed using
the BioDocAnalyze system (Biometra). For competition assays,
8 nM plasmid DNA harbouring an addressed PvuII site was co-
incubated with 32 nM of a 900 bp long PCR fragment
harbouring an unaddressed PvuII site and with 2 nM, 8 nM,
and 320 nM enzyme, respectively. Furthermore, for testing the
specificity of the TALE-PvuII nuclease, we have also carried
out cleavage experiments with plasmid substrates in which the
AvrBs3 recognition sequence was replaced by the AvrBs4
recognition sequence which differ in 8 out of 19 positions from
each other (see Table S1 for plasmid substrates used).
Radioactively labelled PCR product cleavage assay
In order to accurately determine the preference of the TALE-
PvuII constructs for the addressed site (T3-n-P-n-T3, T3-6-P,
where T3 and P are the AvrBs3 target site and the PvuII site,
respectively, separated by n or 6 bp) compared to the
unaddressed site (-P-), radioactively labelled PCR fragments
were generated using [α32P]dATP (Table S1). 20 nM substrate
were incubated with 20 nM enzyme in 20 mM Tris-Ac, 120 mM
K-Ac, 1 mM Mg-Ac, pH 7.5 at 37°C. For competition assays, 20
mM of each substrate and 20 nM enzyme were incubated.
After defined time intervals, samples were analyzed by
polyacrylamide gel electrophoresis. The quantification was
carried out with the Instant Imager system (Packard) using the
Instant Imager software. Initial rates were calculated by linear
regression analysis.
Viability assay
Electrocompetent JM109 E. coli cells, not expressing the
PvuII DNA-methyltransferase, were transfected with 50 ng
plasmid DNA harbouring the genes of the TALE-PvuII variants.
The DNA was mixed with cells and the mixture then placed in
an electroporation cuvette. The transfection was done in an
electroporator (Eppendorf, electroporator 2510) at 1350 V.
Immediately after transfection, cells were resuspended in 900
µl LB-medium and incubated for 1 h at 37°C. Afterwards, 50 µl
of the suspension were spread on an agar plate with ampicillin
and incubated overnight at 37°C. The next day, colonies were
counted and normalized against the control [cells expressing
TALE (AvrBs3)]. The assay was repeated with the E. coli strain
XL10Gold (Stratagene) using 100 ng DNA for the transfection
and 100 µl of the suspension per agar plate. The viability factor
is defined by the ratio of the viable clones of E. coli cultures
either expressing or not expressing the TALE-PvuII variants
[61].
Plasmid cleavage assay in HEK293T cells
HEK293T cells were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Invitrogen). Cells were seeded in 6-well
plates at a density of 500,000 cells/well. After 24 h, cells were
transfected using polyethylenimin (PEI) as described before
[62] with 1 µg of addressed target (T3-6bp-PvuII-6bp-T3) and 4
µg of AvrBs3-PvuII (variants G135W, G53R, A92T),
respectively. Cells were harvested 3 days after transfection,
and total DNA extracted using the QIAamp DNA Mini Kit
(Qiagen). The region of 517 bp surrounding the PvuII site was
amplified by PCR using 50 ng of total DNA as template, along
with 0.2 µM of each primer (5’-gtatcgtccattccgacagcatc and 5’-
ctcgccgaaaatgacccagag), 200 mM dNTPs, and 1 U of Phusion
high fidelity DNA polymerase for 30 cycles. PCR amplicons
were cleaned up using the QIAquick PCR Purification Kit
(Qiagen) and 100 ng DNA was subjected to digestion with 20 U
of PvuII-HF (New England BioLabs).
Cytotoxicity assay in HEK293T cells
Nuclease-associated toxicity was determined basically as
previously described [63]. Briefly, HEK293T cells were seeded
in 24-well plates at a density of 120,000 cells/well. After 24 h,
cells were transfected using PEI with 800 ng of each TALEN-
PvuII expression vectors (AvrBs3-PvuII variants G135W,
G53R, A92T) together with 100 ng of the mCherry expression
vector (kindly provided by Roger Y. Tsien, UC San Diego), and
1.25 µg pUC118. As positive control, 800 ng of expression
vectors encoding the toxic ZFN pair GZF1N/GZF3N [64] were
applied. The cell survival rate was calculated as the decrease
in the number of mCherry-positive cells determined by flow
cytometry (FACSCalibur; BD Biosciences) from days 2 to 5,
normalized to cells transfected with an I-SceI expression
vector.
Results
The goal of our study was to generate a TALE-PvuII fusion
protein that cleaves DNA only at a composite site consisting of
the TALE target site and the PvuII recognition site (addressed
site) but not at any other PvuII site (unaddressed site). For this
purpose, trimmed versions of AvrBs3 [25], a well characterized
natural TALE protein [18,65,66], were fused to either the
homodimeric wild type PvuII or the single chain (sc) variant of
PvuII, in which the two subunits of wtPvuII are covalently linked
via a short peptide linker [59], as shown schematically in Figure
TALE-PvuII Fusion Proteins
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1A. A model of the TALE-PvuII fusion protein in complex with
DNA is shown in Figure 1B.
Altogether, six different fusion proteins with PvuII and
scPvuII, which all carry the T46G substitution that reduces star
activity [58], were prepared (see Materials and Methods).They
differed in the distance between the DNA-binding (AvrBs3 or
AvrBs4) and the DNA-cleavage module (scPvuIIT46G or PvuIIT46G
and variants thereof). The fusion proteins were expressed in E.
coli, purified to homogeneity and tested for their DNA-cleavage
activity towards both addressed and unaddressed PvuII sites.
The ratio between these two activities is reflecting the
specificity of the fusion protein. Two different types of
substrates were used, plasmids and PCR products, the latter
also radioactively labelled to quantify target cleavage
specificity.
Linker length determines specificity of TALE-PvuII
fusion proteins
As the length of the linker between the binding and cleavage
modules plays an important role for activity and specificity of
fusion proteins [53,54], we have compared two linkers, 63-L
and 28-L, to span the distance between the C-terminus of
AvrBs3 and the N-terminus of PvuII. Linker 63-L consists of the
63 amino acids following the last AvrBs3 DNA-binding repeat
and the 16 residues long linker L (see Materials and Methods).
In linker 28-L only 28 residues following the last repeat of
AvrBs3 are present. The DNA cleavage activity of the fusion
proteins was measured with a supercoiled plasmid with an
addressed site (T3-6bp-P-6bp-T3) and for comparison with a
supercoiled plasmid with an unaddressed PvuII site (-P-).
Figure 2 shows that all fusion proteins tested (8 nM) cleave the
supercoiled plasmid (8 nM) with an addressed site to create a
linearized plasmid within minutes at low ionic strength (76 mM).
Under the same conditions, the plasmid substrate with an
unaddressed site is also cleaved, albeit significantly more
slowly. It is noteworthy that the fusion protein with the short
linker is more specific than the fusion protein with the long
linker (Figure 2A). We have therefore used the fusion proteins
with the short 28-L linker in all subsequent experiments.
Figure 1.  TALE-PvuII fusion proteins.  (A) Scheme of the architecture of TALE–PvuII fusion proteins. Left: wtPvuII, a homodimer
in which the DNA-binding module of a TALE protein is fused via a linker of defined length. Right: scPvuII, a monomeric nuclease in
which the DNA-binding module of a TALE protein is fused via a linker of defined length. (B) Model of a TALE–wtPvuII fusion protein.
The fusion protein is a dimer of identical subunits, each composed of a PvuII subunit and a TALE protein. This model was
constructed by aligning the structures of the individual proteins [pdb 1pvi [74] and pdb 3ugm [76]] on a DNA composed of the PvuII
recognition site and two TALE target sites up- and downstream of the PvuII recognition site, separated by 6 bp. The C-termini of the
PvuII subunits and the N-termini of the TALE protein are separated by about 3 nm. This distance must be covered by a peptide
linker of suitable length. The image was generated with PyMol.
doi: 10.1371/journal.pone.0082539.g001
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Furthermore, the PvuII fusion protein seems to be slightly more
specific than the scPvuII fusion protein (Figure 2A and B).
Ionic strength affects the specificity of TALE-PvuII
fusion proteins
Higher ionic strength suppressed non-specific DNA cleavage
by ZFN-PvuII fusion proteins [54]. Therefore we tested if TALE-
PvuII fusion proteins would show higher specificity at ionic
strength comparable to physiological conditions. We found that
at an ionic strength of 143 mM, AvrBs3-28-L-PvuIIT46G did not
cleave unaddressed PvuII sites in detectable amounts even at
a 10-fold excess of enzyme (80 nM) over substrate (8 nM). The
scPvuIIT46G variant was somewhat less specific as compared to
the PvuIIT46G variant (Figure 2C). Thus, similar to ZFN-PvuII
fusion proteins, TALE-PvuII fusions showed enhanced
specificity at physiological ionic strength. All subsequent
experiments were therefore carried out with AvrBs3-28-L-
PvuIIT46G in a buffer with an ionic strength of about 150 mM.
The presence of the PvuII site is essential for cleavage
by TALE-PvuII fusion proteins
For a quantitative determination of the specificity of
AvrBs3-28-L-PvuIIT46G, varying concentrations of enzyme were
challenged with a mixture of a specific substrate (8 nM plasmid
DNA with an addressed PvuII site) and a non-specific substrate
(32 nM PCR fragment with an unaddressed PvuII site). As
shown in Figure 3A, regardless of the relative concentrations of
enzyme and substrate (from 0.25:1 to 40:1) only cleavage of
the addressed site could be observed. Even at a 40-fold
excess of enzyme over addressed sites (40:1) and long
Figure 2.  Analysis of the cleavage activity of AvrBs3-PvuII fusion proteins.  (A) and (B) Comparison of the cleavage rates of
selected AvrBs3-PvuII fusion proteins (as indicated) under low ionic strength: 76 mM (20 mM Tris-Ac, 50 mM K-Ac, 2 mM Mg-Ac,
pH 7.5). In the top row the cleavage of the addressed substrate (T3-6bp-P-6bp-T3) is shown, in the bottom row that of the
unaddressed substrate (-P-). All cleavage experiments were done with 8 nM DNA and 8 nM enzyme. (C) Comparison of the
cleavage rates of an unaddressed substrate by selected AvrBs3-PvuII fusion proteins (as indicated) under physiological ionic
strength: 143 mM (20 mM Tris-Ac, 120 mM K-Ac, 1 mM Mg-Ac, pH 7.5). The experiments were done with an excess of enzyme, the
TALE-scPvuII fusion protein (top, 60 nM enzyme, 6 nM DNA) shows a higher cleavage activity with an unaddressed substrate (-P-)
than the homodimeric TALE-PvuIIT46G fusion protein (bottom, 80 nM enzyme, 8 nM DNA). See the appearance of nicked and
linearized DNA with AvrBs3-28-L-scPvuIIT46G. There is no nicking or cleavage detectable of the unaddressed substrate with
AvrBs3-28-L-PvuIIT46G. oc, open circle; lin, linearized; sc, supercoiled.
doi: 10.1371/journal.pone.0082539.g002
TALE-PvuII Fusion Proteins
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e82539
incubation times, cleavage of the unaddressed site was not
detectable. It is noteworthy that even with an excess of
substrate over enzyme, complete cleavage of substrate is
observed, demonstrating that the TALE-PvuII fusion protein
exhibits turnover.
For a quantitative evaluation of the preference of AvrBs3-28-
L-PvuIIT46G for an addressed over an unaddressed site,
Figure 3.  Analysis of competition cleavage experiments with AvrBs3-PvuII fusion proteins.  (A) Competition cleavage
experiments with AvrBs3-28-L-PvuIIT46G under physiological ionic strength. Shown is the cleavage pattern with supercoiled plasmid
DNA with an addressed site (8 nM) in competition with a PCR fragment (unP) with an unaddressed site (32 nM). The experiment
was carried out with a variable excess of enzyme over plasmid substrate (0.25 to 40-fold). The enzyme shows complete cleavage of
the addressed substrate but no cleavage of the unaddressed substrate, even in an overnight incubation with a 40-fold excess of
enzyme over the addressed plasmid substrate (8 nM) and 10-fold excess over the unaddressed PCR substrate (32 nM). The
brackets indicate the positions where one would expect the products of cleavage of the unaddressed PCR substrate. oc, open
circle; lin, linearized; sc, supercoiled. (B) Quantitative determination of the preference of AvrBs3-28-L-PvuIIT46G for an addressed
(T3-6bp-P-6bp-T3) over an unaddressed site (-P-). The reactions were performed in triplicate under physiological conditions with 20
nM enzyme and 20 nM addressed substrate (squares) and unaddressed substrate (circles), both PCR fragments were radioactively
labelled with [α32P]dATP. The insert shows the primary data: the electrophoretic analysis of the cleavage reaction products using an
Instant Imager. From the fit, a cleavage preference of > 34,000-fold was determined.
doi: 10.1371/journal.pone.0082539.g003
TALE-PvuII Fusion Proteins
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radioactively labelled PCR fragments were used. Figure 3B
shows the kinetics of cleavage of 20 nM PCR fragments with
an addressed site and an unaddressed site, respectively, by 20
nM enzyme. Taking the limits of detection into consideration,
the preference of AvrBs3-28-L-PvuIIT46G for an addressed over
an unaddressed site was >34,000-fold (Figure 3B). This
preference was even superior than the one we had previously
measured for the inactive I-SceI and zinc finger versions of the
PvuII fusions, namely >1,000-fold [53,54].
Target site requirements for cleavage by TALE-PvuII
fusion proteins
So far, only the specificity of AvrBs3-28-L-PvuIIT46G for a
target sequence comprising the AvrBs3 and a PvuII site
(T3-6bp-P-6bp-T3) was analyzed. We were interested to know
whether AvrBs3-28-L-PvuIIT46G would also cleave a target
sequence comprising an AvrBs4 recognition site. AvrBs4 has
the same overall architecture as AvrBs3 but its DNA target
sequence differs in 8 out of 19 positions from the AvrBs3 site.
Figure 4A shows that at equimolar concentrations of enzyme
and substrate (8 nM) only the AvrBs3 but not the AvrBs4 site-
containing DNA target (T4-6bp-P-6bp-T4) was first nicked and
then cleaved.
The experiments reported above were all carried out with a
“tripartite” substrate that contains a central PvuII site and two
flanking AvrBs3 target sites (T3-6bp-P-6bp-T3). We wondered,
whether a “bipartite” substrate that lacks one of the two flanking
AvrBs3 target sites (T3-6bp-P) would also be cleaved by
AvrBs3-28-L-PvuIIT46G. Figure 4B shows that the bipartite
substrate (8 nM) at equimolar concentration with the enzyme
was cleaved almost as efficiently as the tripartite substrate,
whereas an unaddressed substrate was not cleaved (Figure
2B). A substrate lacking the central PvuII site is not cleaved
(data not shown).
It cannot be precisely predicted by modeling of the TALE-
PvuIIT46G fusion protein (Figure 1B), what the optimal distance
between the AvrBs3 and PvuII site for double-strand cleavage
by the AvrBs3-28-L-PvuIIT46G fusion protein would be. We have
therefore produced several DNA substrates with 2, 4, 6 and 8
bp between the AvrBs3 and the PvuII site. As shown in Figure
4C, the distance of 4 and 6 bp is favoured over the others, not
only for AvrBs3-28-L-PvuIIT46G (44-aa linker), but also for
AvrBs3-28-PvuIIT46G (28-aa linker), which has a shorter linker
between the AvrBs3 repeat array and PvuII module. AvrBs3-L-
PvuIIT46G (16-aa linker) with the shortest linker, however,
preferred the substrate with the 2-bp linker over the one with
the 6-bp linker. The different linkers had no influence on the
specificity of the fusion protein (data not shown).
Activity and toxicity of TALE-PvuII fusion proteins in
human cells
We routinely check the activity of our PvuII fusion proteins in
a viability assay in E. coli before testing their activity in human
cells. In the viability assay, E. coli cells not expressing the PvuII
DNA-methyltransferase (M.PvuII) are challenged with the PvuII
fusion proteins. Clones growing in the absence of M.PvuII and
in the presence of TALE-PvuII are picked. Some of them are
subjected to further analysis: the sequence of the open reading
frame coding for the TALE-PvuII protein is determined and the
activity of the protein analyzed in vitro. The most active ones
are then subjected to a cellular plasmid cleavage assay: in the
present study G53R, A92T, G135W. As shown in Figure 5, the
three AvrBs3-PvuII variants, which also carry the high fidelity
mutation T46G, were active in HEK293 cells co-transfected
with a plasmid carrying the target site for AvrBs3-PvuII and one
of the respective nuclease expression vectors [54]. In human
cells, target site (in this case T3-6bp-P-6bp-T3, Figure 5A)
cleavage by the engineered nuclease is followed by error-
prone NHEJ repair, leading to insertions and deletions at the
target site, which can be detected by PCR followed by
restriction with PvuII (Figure 5B). The partial resistance of the
PCR fragment to cleavage with PvuII demonstrates that some
of the isolated target plasmids had been cleaved by the TALE-
PvuII variant. The activity assay showed that the three variants,
AvrBs3-28-L-PvuIIT46G;G53R, AvrBs3-28-L-PvuIIT46G;A92T and
AvrBs3-28-L-PvuIIT46G;G135W had similar activity in human cells.
Nuclease-associated cytotoxicity was determined by co-
transfecting an mCherry expression plasmid and comparing the
decrease of mCherry positive cells to a control nuclease [63].
Figure 5C shows that the three AvrBs3-PvuII variants induced
little cytotoxicity which was slightly higher than that of I-SceI but
considerably less than that of the ZFN pair GZF1N/GZF3N
[64].
Discussion
Genome editing with engineered nucleases was chosen as
Method of the Year 2011 by the editors of Nature Methods, as
it is a powerful tool for studying biological processes [67]. In
principle, it has also the potential to be used for gene targeting
in general and gene therapy in particular, for example to
correct mutations in monogenic hereditary human diseases by
targeted approaches based on homologous recombination
[7,68]. A variety of engineered nucleases are being used or
considered for this purpose (Figure 6). Here, we introduce a
new architecture for engineered nucleases to be used for
genome editing.
The most widely used programmable nucleases are ZFNs
and TALENs followed by the recently introduced CRISPR/Cas-
based nucleases [4]. ZFNs and TALENs differ in their DNA-
binding module but have the same DNA-cleavage module, the
non-specific catalytic domain of the Type IIS restriction
endonuclease FokI. The natural FokI enzyme is a monomeric
protein, both free in solution and when bound to DNA in the
absence of divalent metal ions [43,69]. A flexible linker
connects the DNA-recognition domain with the non-specific
DNA-cleavage domain. For DNA cleavage, FokI dimerization,
which occurs via the catalytic domain, is required [42]. A
productive complex can be formed by various ways [70]: (i.)
two FokI monomers free in solution can associate to form a
dimer which then binds to its recognition sequence GGATG
and, in the presence of Mg2+ ions, cleaves the DNA
downstream of the recognition site, 9 and 13 nucleotides away
in the top and bottom strand, respectively. (ii.) FokI binds to its
recognition site as a monomer and recruits another FokI
monomer free in solution forming a dimer which cleaves the
TALE-PvuII Fusion Proteins
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DNA in the presence of Mg2+ ions. (iii.) On a DNA substrate
with two (or more) recognition sites, the active dimer can be
formed from two FokI monomers each bound to a recognition
site, which means that the DNA between the two recognition
sites is looped out [71,72]; again, cleavage occurs only in the
presence of Mg2+ and is considerably faster on a substrate with
two (or more) recognition sites than on a substrate with one
recognition site [72]. The various ways by which FokI can form
the active dimer implies that cleavage of a ZFN target, i.e. two
ZF recognition sites located adjacent to each other, can occur,
though rarely, by cleavage at half-sites, i.e. at only one ZF
recognition site [44]. This would cause so called off-target
cleavage resulting in unacceptable toxicity. In contrast to
classical FokI-based ZFN and TALENs, PvuII-based TALENs
are dimeric proteins such as the natural PvuII, both in the
absence [73] and the presence of a substrate [74], and thus do
not require dimerization on the target, which eliminates one
source for off-target cleavage. Off-target cleavage can be
greatly reduced, but not fully abolished by rationally
redesigning the ZFN dimer interface to inhibit
homodimerization [45,46,75]. Off-target cleavage specificities
of optimized ZFNs were analyzed by Gabriel et al. [47] and
Figure 4.  Analysis of the cleavage activity of AvrBs3-PvuII fusion proteins on AvrBs3 and AvrBs4 substrates.  (A)
Specificity of cleavage analyzed with the T3-6bp-P-6bp-T3 substrate and the T4-6bp-P-6bp-T4 substrate which differ in 11 (8,
respectively, considering the degeneracy of the TALE recognition code) out of 19 positions from the AvrBs3 target site. No nicking
or cleavage of the AvrBs4 substrate (8 nM) by AvrBs3-28-L-PvuIIT46G (8 nM) could be detected. (B) Cleavage of a “half-site”
substrate by AvrBs3-28-L-PvuIIT46G. The “half-site” substrate is a bipartite substrate consisting of an AvrBs3 recognition site and a
PvuII recognition site (T3-6bp-P). The sc plasmid (8 nM) with the “half-site” was incubated with an equimolar concentration of
AvrBs3-28-L-PvuIIT46G (8 nM). The assay was done under physiological ionic strength and in competition with a 32 nM PCR
fragment (unP) with one unaddressed PvuII site (-P-). Whereas the “half-site” substrate is cleaved almost to completion, the
unaddressed PCR fragment is not cleaved at all. (C) The effect of the distance of the AvrBs3 and the PvuII site on the rate of DNA
cleavage by various AvrBs3-PvuII fusion proteins. 20 nM radioactively labelled PCR fragments with 2 (T3-2-P-2-T3), 4 (T3-4-P-4-
T3), 6 (T3-6-P-6-T3) and 8 (T3-8-P-8-T3) bp between the AvrBs3 and the PvuII site were incubated with 20 nM AvrBs3-28-L-
PvuIIT46G, AvrBs3-28-PvuIIT46G and AvrBs3-L-PvuIIT46G for 60 min.
doi: 10.1371/journal.pone.0082539.g004
TALE-PvuII Fusion Proteins
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e82539
Pattanayak et al. [48]. In vivo cleavage sites were identified
that resembled the intended target site but could not be
predicted in silico. It must be emphasized that off-target
Figure 5.  Activity and toxicity of TALE-PvuII fusion
proteins in human cells.  (A) PCR was performed with the
plasmid from the HEK293 cells resulting in a DNA fragment of
517 bp. * indicates the cleavage site of PvuII. (B) Analysis of
the PCR product (14.5 nM) after digestion with 20 U of PvuII for
1 h. A cleavage-resistant band indicates the loss of the PvuII
site by NHEJ and confirms the activity of the TALE-PvuII fusion
proteins. (C) Cell toxicity of the PvuII-based TALENs. After co-
transfection of a mCherry expression plasmid, cell survival rate
was calculated as the decrease in the number of mCherry-
positive cells from day 2 to day 5 by flow cytometry, normalized
to cells transfected with an I-SceI expression vector. *
Statistically significant differences in toxicities between I-SceI
and TALE-PvuII fusion proteins are indicated (P-values) .
doi: 10.1371/journal.pone.0082539.g005
cleavage is likely to also be a problem with other engineered
nucleases that use the catalytic domain of FokI as DNA-
cleavage module, such as TALENs.
After we had recently shown that in ZFNs the catalytic
domain of FokI can be replaced by PvuII [54], we now
demonstrate that also in TALENs PvuII can take over the role
of the DNA-cleavage module. Substituting the non-specific
domain of FokI for PvuII (or other specific nucleases) has the
advantage that an extra element of specificity, the PvuII
recognition site CAGCTG, is added to the TALE protein. The
challenge of designing TALE-PvuII fusion proteins as highly
specific programmable nucleases is to take precautions that a
PvuII site that is not addressed by a TALE protein recognition
site is not attacked by the PvuII module in the TALE-PvuII
fusion protein. There are in principle two different strategies to
achieve this, as shown for ZF-PvuII [54] and I-SceI*-PvuII [53]
fusion proteins: (i.) One could weaken the interaction of PvuII
to the PvuII recognition site by introducing amino acid
substitutions, such that PvuII as the cleavage module in the
fusion protein is absolutely dependent on the TALE protein for
a productive interaction with the composite site consisting of a
TALE recognition site and a PvuII recognition site, i.e. the
addressed PvuII recognition site. (ii.) Another possibility is to
construct the linker between the DNA-binding and DNA-
cleavage module such that PvuII cannot make a productive
interaction with a PvuII site, unless the TALE protein has made
contact with its binding site and thereby released the DNA
cleavage module PvuII from an inhibited conformation. We
believe that in the TALE-PvuII construct that we have
produced, PvuII presumably is sterically hindered by the TALE
protein to form an activated transition state complex with the
PvuII recognition site, unless there is a strong interaction
between the DNA binding domain of the TALE protein and the
TALE target site.
PvuII is a homodimeric protein; this means that also the
TALE-PvuII fusion proteins are homodimers. Because a single
chain version (sc) of PvuII has been described [59], we also
generated monomeric TALE-scPvuII fusion proteins. We have
prepared several versions of the TALE-PvuII fusion protein, all
of which carry the T46G mutation which exhibits less star
activity than wildtype PvuII [58]. The TALE-PvuII fusion
proteins were tested on tripartite substrates which contained a
PvuII site between two TALE recognition sites, e.g. TALE-6 bp-
PvuII-6 bp-TALE. The homodimeric TALE-PvuII with the 28-L
linker turned out to be more specific, i.e. showed less
unaddressed cleavage, than the single chain variant and the
variant with the 63-L linker. Therefore, all subsequent
experiments were done with the homodimeric fusion protein
with the short linker. At physiological ionic strength (~150 mM),
no unaddressed cleavage was observed, not even at excess of
enzyme (up to 10-fold) over substrate and long incubation
times (up to 24 hours in a plasmid cleavage assay). The
specificity of the TALE-PvuII fusion protein was quantified with
radioactively labelled addressed and unaddressed substrates
and found to be >34,000-fold for the addressed substrate. The
TALE-PvuII fusion protein prefers a spacer length (distance
between TALE and PvuII recognition sequences) of 4 to 6 bp.
TALE-PvuII Fusion Proteins
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Remarkably, the TALE-PvuII fusion protein also accepts half-
sites, i.e. bipartite recognition sites, e.g. TALE-6bp-PvuII. We
suggest that binding of a single AvrBs3 module to the TALE
binding site of the substrate, leaving the other AvrBs3 module
making non-specific contacts with the DNA, is sufficient to
activate PvuII. This may be due to the rather high ratio of
enzyme vs. substrate in vitro which can hardly be achieved in
cellula. Still, this finding implies that precision genome
engineering can be done by cleavage of a site consisting of
one TALE target site adjacent to a PvuII site. If they are
sufficiently specific, this would be an advantage over TALENs
(and ZFNs) based on the catalytic domain of FokI, which
require heterodimerization of two proteins with different target
recognition domains. However, we have recently also
engineered active obligate heterodimeric variants of TALEN-
PvuII (Yanik et al, in preparation). This will allow us to target
extended recognition sequences.
The TALE-PvuII fusion proteins that we have produced are
highly active and specific in vitro. To answer the question
whether they are active in vivo, we have tested them in human
cells using a cellular plasmid cleavage assay. This assay
showed that all TALE-PvuII fusion proteins were active in
HEK293T cells. When assaying cytotoxicity associated with
expression of the TALE-PvuII fusion proteins, they exhibited
almost as little toxicity as I-SceI and performed better than a
toxic reference ZFN. PvuII-based TALENs (and ZFNs) require
the presence of a PvuII site as part of a potential target site,
which may be considered a disadvantage. However, since
PvuII sites statistically occur on average within a few thousand
base pairs, it should be possible to find a suitable target sites
for TALE-PvuII fusion proteins.
Conclusions
In the present paper, we demonstrated that TALENs can be
produced with the restriction endonuclease PvuII as DNA-
cleavage module instead of the most frequently used non-
specific cleavage domain of FokI. The TALE-PvuII fusion
protein does not exhibit any non-specific cleavage at
unaddressed PvuII sites nor at any other site, as was
demonstrated in experiments in which DNA carrying
unaddressed PvuII sites was incubated with a high molar
Figure 6.  Engineered highly specific endonucleases that can be used for gene targeting by introducing a double-strand
break into a complex genome and thereby stimulating homologous recombination.  With the exception of engineered homing
endonucleases (“meganucleases”) in which the function of DNA binding and DNA cleavage is present in the same polypeptide chain
[77], the other engineered nucleases consist of separate DNA-binding (green) and DNA-cleavage (blue) modules. Zinc finger
nucleases and TALE nucleases usually have the non-specific cleavage domain of the restriction endonuclease FokI as DNA-
cleavage module, but as shown recently and in the present paper the restriction endonuclease PvuII can also be used for this
purpose [54]. PvuII has also been employed in TFO-linked nucleases [49] and in protein fusions (with catalytically inactive I-SceI)
[53] as DNA-cleavage module. Zinc finger nucleases, TALE nucleases and TFO-linked nucleases are programmable, as are the
RNA-mediated nucleases [36] [modified after [3]] .
doi: 10.1371/journal.pone.0082539.g006
TALE-PvuII Fusion Proteins
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e82539
excess of the TALE-PvuII fusion protein for up to 24 hours.
Under these conditions, addressed PvuII sites were cleaved
within minutes. In principle, TALE-PvuII fusion proteins can be
produced as homodimers or as monomers with scPvuII. The
TALE-PvuII fusion proteins turned out to be active in HEK293T
cells, with almost as little toxicity as I-SceI. Taken together, we
suggest that TALE-PvuII fusion proteins should be considered
as suitable alternatives to classical ZFNs and TALENs. Of
course, highly specific nucleases, regardless of which DNA-
cleavage module they contain, need to be tested in vivo for
their specificity which means for off-target cleavage, as it was
done for ZFNs in a genome-wide analysis [47,48]. Finally, we
have now expanded the “tool box” for gene targeting by a
double-strand specific TALE-PvuII nuclease, which might be
the nuclease of choice for gene disruption, whereas a nicking
nuclease, such as TALE-MutH [57], might be more useful for
gene replacement where one wants to avoid non-homologous
end joining (NHEJ).
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